The National Agency for Food and Drugs Administration and Control (NAFDAC) has issued a public warning about the presence of pre-filled pens falsely labelled as the diabetes medication Ozempic.
The reports of falsification emerged following a surge in demand for Ozempic, resulting in a global shortage.
According to a NAFDAC statement, the pens have batch numbers, 2D barcodes, and distinctive serial numbers that are exact replicas of those on genuine Ozempic packs.
The agency urged importers, distributors, retailers, healthcare providers, and patients to exercise utmost caution and vigilance within the supply chain to prevent the importation, distribution, sale, or administration of falsified or substandard medicinal products.
“Individuals in possession of the falsified Ozempic product are strongly advised not to use it. Those who have used the product or experienced adverse reactions are encouraged to seek immediate medical advice from qualified healthcare professionals.”
To ensure public safety, NAFDAC called on healthcare professionals and consumers to report any suspicions of substandard or falsified medicines to the nearest NAFDAC office.